Our data reflects this latter notion, as we found minimal differences in the immune cells within the tumor microenvironment of WT and CB2-/- mice receiving DMBA/TPA coupled with significant systemic immune alterations and significant differences in papilloma development, showing that endogenous CB2 activation is potentially altering the activity and expression of specific tumor growth factors. The gene discussed is CNR2; the disease is neoplasm.